A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors

- Age 18 years or older;

- Patients with histologically or cytologically confirmed, advanced solid tumors which have progressed despite standard therapy or for whom no standard therapy exists.

- Patients must have at least one measurable or non-measurable lesion (dose escalation only) as defined by RECIST v1.1

- Eastern Cooperative Oncology Group performance score 0 to 2;

- Patients with symptomatic CNS metastases;

- Patients who have a known history of hepatitis C or chronic active hepatitis B or a known diagnosis of HIV

- Any significant ophthalmologic abnormality

- Patients who have any severe and/or uncontrolled medical conditions

- Significant gastrointestinal abnormalities,

- Patients who have impaired cardiac function or clinically significant cardiac diseases,

- Chemotherapy, biologic therapy, immunotherapy, radiotherapy or investigational agents within 5 half-lives or within 4 weeks (whichever is longer) prior to administration of the first dose of study drug on Day 1 or have not recovered from the side effects of such therapy;

- Treatment with third generation EGFR inhibitors

- Major surgery/surgical therapy for any cause within 4 weeks of Screening;